Session Item

There is growing evidence that hypofractionated radiotherapy (HFRT) could be a possible preoperative therapeutic approach in patients with localized soft tissue sarcomas (STS). Despite the encouraging data from several prospective phase 2 single-arm clinical trials with moderate and extreme hypofractionation, HFRT is still considered experimental in STS. HFRT was introduced in several cancers like rectal, prostate, and breast cancer. Moreover, it has a strong radiobiological rationale, mostly due to the predicted low α/β ratio for STS. Highly conformal radiotherapy techniques enabled significant sparing of healthy tissues that are at risk of late complications theoretically associated with HFRT. Furthermore, fears that HFRT could result in an unacceptably high rate of late radiation-induced toxicity was not confirmed in hypofractionated treatment for breast and prostate cancer patients where cosmetic and functional outcome played a very important role in conducted clinical trials. Are we ready for HFRT in SRS?